NCT05826574 is a Phase 1 clinical trial of Brensocatib in Healthy Volunteers, sponsored by Insmed Incorporated.

Who is sponsoring NCT05826574?

NCT05826574 is sponsored by Insmed Incorporated.

What drugs are being tested in NCT05826574?

Interventions in NCT05826574: Brensocatib, Rifampin, Esomeprazole.

What condition does NCT05826574 study?

NCT05826574 studies Healthy Volunteers.

Is NCT05826574 still recruiting?

NCT05826574 is currently completed. Last updated 21 August 2023.

Last reviewed 2023-08-21 · How we verify

NCT05826574

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or Esomeprozole in Healthy Participants

Completed Phase 1 Last updated 21 August 2023

What this trial tests

Phase 1 trial testing Brensocatib in Healthy Volunteers in 32 participants. Completed in 16 July 2023.

Timeline

10 May 2023

Primary endpoint
16 July 2023

16 July 2023

Quick facts

Lead sponsor	Insmed Incorporated
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	32
Start date	10 May 2023
Primary completion	16 July 2023
Estimated completion	16 July 2023
Sites	1 location across United States

Drugs / interventions tested

Brensocatib (BRENSOCATIB) — full drug profile →
Rifampin — full drug profile →
Esomeprazole (esomeprazole) — full drug profile →

Conditions studied

Healthy Volunteers — all drugs for Healthy Volunteers →

Sponsor

Insmed Incorporated — full company profile →

Who can join

Adults 18 to 55, any sex, with Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary purpose of this study is to assess the effects of rifampin on the PK of brensocatib in Part 1 of the study and to assess the effects of esomeprazole on the PK of brensocatib in Part 2 of the study.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Cathepsin C in health and disease: from structural insights to therapeutic prospects.
Chitsamankhun C, Siritongtaworn N, Fournier BPJ, Sriwattanapong K, et al · · 2024 · cited 15× · PMID 39164687 · DOI 10.1186/s12967-024-05589-7

Verify or expand the search:

Other trials of Brensocatib

Trials testing the same drug.

NCT06685835 — A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS) · Phase 2 · active not recruiting
NCT06178783 — A Study of the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in Healthy Participants · Phase 1 · completed
NCT06013241 — A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSs · Phase 2 · completed
NCT05965570 — A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy P · Phase 1 · completed
NCT05517525 — A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With Normal Hep · Phase 1 · completed

Other recruiting trials for Healthy Volunteers

Currently open trials in the same condition.

NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
NCT07495813 — A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease · Phase 1 · recruiting
NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting

Other Insmed Incorporated trials

Trials by the same sponsor.

NCT07481981 — A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants · Phase 3 · not yet recruiting
NCT07234032 — An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertens · Phase 3 · not yet recruiting
NCT07179380 — Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension · Phase 3 · recruiting
NCT07102316 — A Study to Assess the Relative Bioavailability After a Single Inhalation Administration of Treprostinil Palmitil Inhalat · Phase 1 · completed
NCT06685835 — A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS) · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05826574 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Insmed Incorporated
Last refreshed: 21 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05826574.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing